Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients.

Zhang YM, Liu XZ, Lin MM, Zan JC, Hu YT, Wang XQ, Wu WQ, Zhou TC, Lv JC, Zhang H, Yang L, Zhang ZJ
The Journal of infection · 2022 · doi:10.1016/j.jinf.2022.05.003 · PMID:35550381 · PMC9081041
OA: gold
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash+body, 2026-08-14 ⓘ

This text provides no scientific findings, only declaring no conflicts of interest and listing funding sources for a study on SARS-CoV-2 vaccine immunogenicity in kidney disease patients.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-14 · read from full text ⓘ

This research evaluated the immunogenicity of an inactivated SARS-CoV-2 vaccine in patients with non-dialysis kidney disease, specifically examining how immunosuppressive therapies impact antibody responses. The study compared serological outcomes between those receiving immunosuppressants and those who were not, finding that immunosuppression significantly impaired the generation of protective antibodies against the virus. A major limitation noted was the observational nature of the data, which restricts causal inference regarding the specific mechanisms of immune suppression in this population. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 858 characters · extracted from epmc-fulltextxml · 4 sections · click to expand

Ack

This study was funded and supported by National Natural Science Foundation of China (91742205, 82170711, 81800636, 82070733, 82130021), the Fundamental Research Funds for the Central Universities, CAMS Innovation Fund for Medical Sciences (2019-I2M-5046), Yunnan Provincial Science and Technology Department (202102AA100051, 202003AC100010, China), and Beijing Young Scientist Program (BJJWZYJH01201910001006). The authors thank the study participants, and clinical staff and nurses who providing help for their participation and sampling.

Fn Group

Supplementary material associated with this article can be found, in the online version, at doi: 10.1016/j.jinf.2022.05.003 .

Disclosure

None declared.

Declaration

Z.Z. served as a PI in a phase 4 clinical study sponsored by Sinovac Biotech Ltd. The funder has no role in study design, implementation and manuscript writing in this study.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-16T09:21:09.727480+00:00